| 2025-12-12 |
详情>>
股本变动：
变动后总股本417.58万股
变动原因 ▼▲
- 原因：
- Common Stock offered 440,000 shares by the company
|
| 2025-12-11 |
详情>>
内部人交易：
Lizak Carol R.等共交易5笔
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-22.61美元,归母净利润-3037.3万美元,同比去年增长-6.3%
|
| 2025-11-10 |
股东大会：
将于2025-12-08召开股东大会
会议内容 ▼▲
- 1.Approving, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock issuable upon exchange of shares of our Series N Perpetual Preferred Stock, par value $0.0001 per share (the “Series N Preferred Stock”) issued to certain accredited investors;
2.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of shares of our Common Stock (the “New PIPE Shares”) and a pre-funded warrant to purchase shares of Common Stock (the “Pre-Funded PIPE Warrant” and, together with the PIPE Shares and shares of Common Stock underlying the Pre-Funded PIPE Warrant, the “New PIPE Securities”) issued by the Company pursuant to that certain securities purchase agreement, dated September 28, 2025, between the Company and the purchaser named therein (the “New PIPE Purchase Agreement”);
3.Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2.
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-26.78美元,归母净利润-2087.1万美元,同比去年增长-11.5%
|
| 2025-08-14 |
财报披露：
美东时间 2025-08-14 盘前发布财报
|
| 2025-07-21 |
股东大会：
将于2025-08-19召开股东大会
会议内容 ▼▲
- 1.Electing three Class I director;
2.Ratifying the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.Approving an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 307,670 shares and extend the remaining term of the 2014 Plan to ten years;
4.Approving, for purposes of Nasdaq Listing Rule 5635(d) (“Rule 5635(d)”), the issuance of shares of our Common Stock issuable upon exchange of shares of our Series L Perpetual Preferred Stock, par value $0.0001 per share (the “Series L Preferred Stock”) issued to certain accredited investors;
5.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of shares of our Common Stock issuable upon exchange of shares of our Series M Perpetual Preferred Stock, par value $0.0001 per share (the “Series M Preferred Stock”) issued to certain accredited investors;
6.Approving, for purposes of Nasdaq Listing Rules 5635(c) and Rule 5635(d), the issuance of up to an aggregate of 1,409,732 shares of our Common Stock upon conversion of certain of our 6% convertible promissory notes and exercise of related warrants to purchase shares of Common Stock issued by the Company pursuant to note exchange and warrant purchase agreements, dated June 24, 2025, between the Company and the purchasers named therein;
7.Approving a proposal to grant discretionary authority for the Company to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve proposals (iii), (iv), (v) and (vi).
8.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-16.7美元,归母净利润-1046.4万美元,同比去年增长-13.42%
|
| 2025-04-26 |
复牌提示：
2025-04-25 13:52:46 停牌，复牌日期 2025-04-25 13:57:46
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-130.69美元,归母净利润-3849.2万美元,同比去年增长6.80%
|
| 2025-03-24 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2025-02-24 |
股东大会：
将于2025-03-13召开股东大会
会议内容 ▼▲
- 1.Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect, if approved and effected at all, a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-15 and not greater than 1-for-40. The exact ratio, if approved and effected at all, will be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before the one-year anniversary of the approval of this proposal, without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”);
2.Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1.
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-4.89美元,归母净利润-2857.2万美元,同比去年增长11.07%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-15.93美元,归母净利润-1871.8万美元,同比去年增长23.14%
|
| 2024-05-22 |
详情>>
拆分方案：
每60.0000合并分成1.0000股
|
| 2024-05-21 |
股东大会：
将于2024-06-21召开股东大会
会议内容 ▼▲
- 1.Electing one Class III director;
2.Ratifying the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.Approving, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached Proxy Statement;
4.Approving an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 45,500,000 shares (equivalent to 758,333 shares following the 1-for-60 reverse stock split to be effectuated on May 23, 2024);
5.Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4;
6.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.06美元,归母净利润-922.6万美元,同比去年增长24.39%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-1.79美元,归母净利润-4130万美元,同比去年增长12.97%
|
| 2024-03-15 |
股东大会：
将于2024-04-09召开股东大会
会议内容 ▼▲
- 1.Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect, if approved and effected at all, a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-2 and not greater than 1-for-150. The exact ratio, if approved and effected at all, will be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before the one-year anniversary of the approval of this proposal, without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”);
2.Approving the issuance of shares of our Common Stock issuable upon exchange of shares of our Series J Perpetual Preferred Stock, par value $0.0001 per share (the “Series J Preferred Stock”) issued to certain accredited investors in accordance with Nasdaq Listing Rule 5635(d) (“Rule 5635(d)”);
3.Approving, for purposes of Rule 5635(d), the issuance of 18,837,500 shares of Common Stock to certain accredited investors pursuant to the exchange agreements, dated February 27, 2024, between the Company and such investors;
4.Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2 and 3.
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.21美元,归母净利润-3213万美元,同比去年增长19.42%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-2.14美元,归母净利润-2435.2万美元,同比去年增长10.97%
|
| 2023-05-31 |
股东大会：
将于2023-07-07召开股东大会
会议内容 ▼▲
- 1.Electing one (1) Class II director (Proposal 1);
2.Ratifying the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Proposal 2);
3.Approving the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”), issuable upon exercise of warrants and conversion of preferred stock issued and to be issued to certain accredited investors in accordance with Nasdaq Listing Rule 5635(d) (Proposal 3);
4.Approving an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 2,700,000 shares and extend the remaining term of the 2014 Plan to ten years (Proposal 4);
5.Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3 and/or Proposal 4 (Proposal 5);
6.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-01-23 |
详情>>
拆分方案：
每75.0000合并分成1.0000股
|
| 2022-11-28 |
股东大会：
将于2023-01-20召开股东大会
会议内容 ▼▲
- 1.Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”) (Proposal 1);
2.Approving, pursuant to Nasdaq Marketplace Rule 5635(d) (“Rule 5635(d)”), the issuance of our Common Stock (and/or securities convertible into or exercisable for our Common Stock) equal to 20% or more of the Common Stock outstanding before the issuance in one or more non-public capital raising transactions (Proposal 2);
3.Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2 (Proposal 3).
|
| 2022-08-29 |
股东大会：
将于2022-09-30召开股东大会
会议内容 ▼▲
- 1.Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”), to increase the number of authorized shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”) from 150,000,000 shares to 298,000,000 shares and a corresponding increase in the total number of shares the Company is authorized to issue from 204,475,074 shares to 352,475,074 shares (Proposal 1);
2.Approving, for purposes of Nasdaq Rules 5635(b) and 5635(d), the issuance of shares of Common Stock to SynWorld Technologies Corporation (“SynWorld”) pursuant to that certain License and Services Agreement, dated June 28, 2022, by and among the Company, SynWorld, C&E Telecom, LTD and Tao Wang, as amended (the “License Agreement”) (Proposal 2);
3.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of shares of Common Stock upon the exchange of a royalty interest previously issued by the Company to an accredited investor (Proposal 3);
4.Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2 and 3
|
| 2022-04-27 |
股东大会：
将于2022-06-10召开股东大会
会议内容 ▼▲
- 1.Electing three (3) Class I directors (Proposal 1);
2.Ratifying the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (Proposal 2);
3.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”) upon the exchange of certain royalty interests and a promissory note previously issued by the Company to certain accredited investors (Proposal 3);
4.Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3 (Proposal 4);
5.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-09-03 |
详情>>
拆分方案：
每3.0000合并分成1.0000股
|
| 2021-04-13 |
股东大会：
将于2021-05-13召开股东大会
会议内容 ▼▲
- 1.Electing one (1) Class III director (Proposal 1);
2.Ratifying the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (Proposal 2);
3.Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”), to increase the number of authorized shares of Common Stock from 150,000,000 shares to 290,000,000 shares (Proposal 3);
4.Approving, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached Proxy Statement (Proposal 4);
5.Indicating, on a non-binding advisory basis, the frequency of future advisory votes to approve the compensation paid by us to our named executive officers (Proposal 5);
6.Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3 (Proposal 6);
7.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-12-10 |
股东大会：
将于2020-12-09召开股东大会
会议内容 ▼▲
- 1.Approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-2 and not greater than 1-for-20, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before December 9, 2021 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”) (Proposal 1);
2.Approve a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 (Proposal 2).
3.Such other business as properly may come before the Special Meeting or any adjournment or postponement thereof.
|
| 2020-12-10 |
股东大会：
将于2020-12-22召开股东大会
会议内容 ▼▲
- 1.Approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-2 and not greater than 1-for-20, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before December 9, 2021 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”) (Proposal 1);
2.Approve a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 (Proposal 2).
3.Such other business as properly may come before the Special Meeting or any adjournment or postponement thereof.
|
| 2020-06-19 |
股东大会：
将于2020-07-21召开股东大会
会议内容 ▼▲
- 1.Approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of our outstanding common stock upon the exercise of our Series 3 Warrants pursuant to the alternate cashless exercise feature set forth therein, with the right for such potential exercise to occur less than six months following the issuance date of the Series 3 Warrants (Proposal 1);
2.Approve an amendment to the Company's 2014 Stock Incentive Plan (the "2014 Plan") to increase the number of shares of common stock authorized for issuance under the 2014 Plan by 234,200 shares (Proposal 2);
3.Approve an amendment to the Company's Third Amended and Restated Certificate of Incorporation, as amended (the "COI"), to decrease the number of authorized shares of Common Stock to 130,000,000 shares (Proposal 3).
4.Such other business as properly may come before the Special Meeting or any adjournment or postponement thereof.
|
| 2020-04-13 |
股东大会：
将于2020-05-15召开股东大会
会议内容 ▼▲
- 1.Electing one (1) Class II director (Proposal 1);
2.Approve an amendment to the Jaguar Health, Inc. 2014 Stock Incentive Plan to increase the annual replenishment of the share pool to five percent (5%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year (Proposal 2);
3.Approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 68,807 shares of Common Stock to Oasis Capital, LLC ("Oasis Capital") as consideration for Oasis Capital's commitment, pursuant to the Company's equity purchase agreement with Oasis Capital, to purchase from the Company, from time to time, up to $2,000,000 shares of Common Stock (Proposal 3);
4.Ratifying the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2020 (Proposal 4);
5.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-06-07 |
详情>>
拆分方案：
每70.0000合并分成1.0000股
|
| 2019-04-29 |
股东大会：
将于2019-05-24召开股东大会
会议内容 ▼▲
- 1.Electing three (3) Class I directors
2.Approving the adoption of an amendment to the Company's Third Amended and Restated Certificate of Incorporation (the "COI") to effect a reverse stock split of the Company's issued and outstanding voting common stock, par value $0.0001 per share (the "Common Stock") at a ratio not less than 1-for-30 and not greater than 1-for-70, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company's board of directors and publicly announced by the Company on or before November 3, 2019 without further approval or authorization of the Company's stockholders (the "Reverse Stock Split")
3.Approving an amendment to the Company's 2014 Stock Incentive Plan (the "2014 Plan") to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan such that the aggregate authorized but unissued shares under the 2014 Plan shall equal 12.5% of the issued and outstanding shares of Common Stock on a fully diluted basis calculated as of the earlier of (A) the day immediately after the consummation of the Company's next underwritten public equity offering with gross proceeds of $5 million or more or (B) July 31, 2019 (collectively, the "Calculation Date"), contingent upon the Reverse Stock Split being approved and effected in accordance with Proposal 2 on, or prior to, the Calculation Date
4.Approving, for purposes of Nasdaq Rules 5635(c) and 5635(d), the issuance of shares of Common Stock upon the exchange of promissory notes and exercise of warrants in one or more private placement transactions
5.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of shares of Common Stock upon the exercise of a warrant issued in connection with the cancellation of a letter of credi
6.Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1-5
7.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-02-25 |
股东大会：
将于2019-02-28召开股东大会
|
| 2019-01-18 |
股东大会：
将于2019-02-25召开股东大会
会议内容 ▼▲
- 1.Approving the amendment of the Company's 2014 Stock Incentive Plan (the "2014 Plan") to allow for a stock exchange program under which eligible Company employees and consultants (excluding directors and executive officers) would have the opportunity to exchange certain underwater stock options for a lesser number of RSUs (Proposal 1);
2.Approving an amendment of the 2014 Plan to allow for a stock exchange program under which eligible Company directors and executive officers (excluding other employees) would have the opportunity to exchange certain underwater stock options for a lesser number of RSUs (Proposal 2);
3.Approving an amendment of the 2014 Plan to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 3,533,826 shares (Proposal 3);
4.Approving an amendment of the 2014 Plan to extend the annual evergreen provision for a period of five (5) years up to and including January 1, 2024 (Proposal 4);
5.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of up to 8,000,000 shares of Common Stock that may be issued to Chicago Venture Partners, L.P. ("CVP") upon exchange of the outstanding balance (including interest thereon), or any portion thereof, of the promissory notes issued by the Company to CVP with an outstanding balance, including accrued and unpaid interest as of December 31, 2018, equal to $6,344,943 (collectively, the "CVP Notes"), subject to the terms of the CVP Notes and one or more exchange agreements that may be entered into from time to time between the Company and CVP (the "CVP Notes Exchange") (Proposal 5);
6.Approving, for purposes of Nasdaq Rule 5635(d), the issuance of up to 13,633,333 shares of Common Stock that may be issued at the Company's discretion from time to time to Oasis Capital, LLC ("Oasis Capital") under an equity line, pursuant to the common stock purchase agreement, dated January 7, 2019, between the Company and Oasis Capital (Proposal 6);
7.Approving a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1-6 (Proposal 7).
|
| 2018-06-01 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2018-04-24 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.Ratifying the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2018 (Proposal 1);
2.Approving, for purposes of Nasdaq Rule 5635(b), the removal of the 19.99% Limitation (as defined in the accompanying proxy statement) with respect to the as-converted voting rights and conversion of the Company's Series A Convertible Participating Preferred Stock into shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock") (which such 19.99% Limitation would otherwise limit the conversion and as-converted voting rights of the Company's Series A Convertible Participating Preferred Stock to no more than 19.99% of the Company's Common Stock outstanding prior to such issuance) (Proposal 2);
3.Approving the adoption of an amendment to the Company's Third Amended and Restated Certificate of Incorporation (the "COI") to effect a reverse stock split of the Company's issued and outstanding Common Stock at a ratio not less than 1-for-11 and not greater than 1-for-15, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company's board of directors and publicly announced by the Company on or before June 30, 2018 without further approval or authorization of the Company's stockholders (the "Reverse Stock Split") (Proposal 3);
4.Approving the adoption of an amendment to the COI to decrease the number of authorized shares of Common Stock to 150,000,000 shares, contingent upon the Reverse Stock Split in Proposal 3 being approved and effected (Proposal 4);
5.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-02-15 |
股东大会：
将于2018-03-12召开股东大会
会议内容 ▼▲
- 1. Approve an amendment to the Company's Third Amended and Restated Certificate of Incorporation (the "COI") to increase the number of authorized shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), from 250,000,000 shares to 500,000,000 shares;
2. Approve an amendment to the COI to effect a reverse stock split at a ratio not less than 1-for-1.2 and not greater than 1-for-10, with the exact ratio, if effected at all, to be set within that range at the discretion of the Company's board of directors before June 30, 2018 without further approval or authorization of the Company's stockholders (the "Reverse Stock Split");
3. Approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of Common Stock in one or more non-public capital raising transactions at a price that may be less than the greater of book or market value of our Common Stock;
4. Approve the amendment of the Company's 2014 Stock Incentive Plan (the "2014 Plan") to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by up to 41,060,000 shares;
5. Approve a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 through 4.
|
| 2017-12-01 |
股东大会：
将于2017-12-15召开股东大会
会议内容 ▼▲
- 1.Approve, pursuant to Nasdaq Listing Rules 5635(b) and (d), the issuance of up to an aggregate of 17,808,144 shares of Jaguar Common Stock that may be issued to (i) Chicago Venture Partners, L.P. ("CVP") upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note, due August 2, 2018, issued by Jaguar to CVP in the original principal amount of $2,155,000 (the "CVP Note"), subject to the terms of the CVP Note, and (ii) Iliad Research and Trading, L.P. ("Iliad"), an affiliate of CVP, upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note proposed to be issued by Jaguar to Iliad in the original principal amount of $1,375,000 (the "Iliad Note"), subject to the terms of the Iliad Note, such aggregate shares constituting approximately 19.9% of our outstanding shares of Common Stock assuming conversion of the non-voting common stock (Proposal 1);
2.Approve a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 (Proposal 2).
|
| 2017-04-17 |
股东大会：
将于2017-05-08召开股东大会
会议内容 ▼▲
- 1.Electing two (2) Class II directors;
2.Ratifying the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2017;
3.Approving, pursuant to Nasdaq Listing Rule 5635(d), the issuance of additional shares of our common stock to Aspire Capital Fund, LLC pursuant to the common stock purchase agreement dated June 8, 2016;
4.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-14召开股东大会
会议内容 ▼▲
- 1.Electing two (2) Class I directors;
2.Ratifying the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2016;
3.Approving the amendment of the Jaguar Animal Health, Inc. 2014 Stock Incentive Plan (the "2014 Plan") to increase the number of shares of Company common stock authorized for issuance under the 2014 Plan by 1,550,000 shares;
4.Such other business as properly may come before the Annual Meeting or any adjournment or postponement thereof.
|